AI reads ECGs to stop heart failure before it starts
NCT ID NCT07355023
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study uses artificial intelligence to analyze electrocardiograms (ECGs) and identify people at high risk for developing left ventricular dysfunction, a type of heart muscle weakness. Researchers will then see if giving standard heart medications—like ACE inhibitors, beta-blockers, and SGLT2 inhibitors—can lower that risk. The study involves 5,000 participants and uses existing medical records to simulate a clinical trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- guideline-directed medical therapies (ACE inhibitors, ARBs, beta-blockers, SGLT2 inhibitors)
- What this could lead to
- If successful, this could show that AI-powered ECG screening plus early medication can prevent heart failure in at-risk people.
- What could go wrong
- This is a retrospective study, not a randomized trial, so results may be less reliable. It also relies on existing medical records, which can have missing or inconsistent data.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEFT VENTRICULAR (LV) SYSTOLIC DYSFUNCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tri-Service General Hospital
RECRUITINGTaipei, Taipei, 11490, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.